An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease (SHIELD-4)
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Sponsor: GlaxoSmithKline
Terminated
This trial was terminated. No reason was provided.
A PHASE3 clinical study on Crohn's Disease, this trial is terminated or withdrawn. The trial is conducted by GlaxoSmithKline and has accumulated 10 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 5 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Sep 2017 — Feb 2018 [monthly]
Terminated PHASE3
-
May 2017 — Sep 2017 [monthly]
Terminated PHASE3
-
Feb 2017 — May 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Aarhus, Denmark , Adelaide, Australia , Afula, Israel , Aichi, Japan , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Athens, Greece , Aurora, United States , Austin, United States and 182 more locations